10x Genomics (NASDAQ:TXG) Sets New 12-Month Low at $33.47

10x Genomics, Inc. (NASDAQ:TXG - Get Free Report)'s share price reached a new 52-week low on Monday . The stock traded as low as $33.47 and last traded at $33.54, with a volume of 219999 shares traded. The stock had previously closed at $34.55.

Wall Street Analyst Weigh In

Several research firms have weighed in on TXG. Stifel Nicolaus lowered their price target on shares of 10x Genomics from $68.00 to $63.00 and set a "buy" rating for the company in a research note on Friday, February 16th. Barclays lowered their price target on shares of 10x Genomics from $55.00 to $45.00 and set an "overweight" rating for the company in a research note on Wednesday, April 10th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $60.88.

10x Genomics Price Performance

The company has a market capitalization of $3.92 billion, a P/E ratio of -15.92 and a beta of 1.90. The stock's 50 day moving average is $41.43 and its 200-day moving average is $43.34.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings data on Thursday, February 15th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.05). The company had revenue of $183.98 million for the quarter, compared to the consensus estimate of $182.73 million. 10x Genomics had a negative net margin of 41.17% and a negative return on equity of 28.82%. The firm's revenue for the quarter was up 17.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.15) EPS. On average, equities research analysts anticipate that 10x Genomics, Inc. will post -1.47 EPS for the current year.

Insider Activity at 10x Genomics

In other 10x Genomics news, CEO Serge Saxonov sold 1,000 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $49.53, for a total value of $49,530.00. Following the transaction, the chief executive officer now directly owns 855,381 shares in the company, valued at $42,367,020.93. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other 10x Genomics news, CEO Serge Saxonov sold 1,000 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $49.53, for a total value of $49,530.00. Following the transaction, the chief executive officer now directly owns 855,381 shares in the company, valued at $42,367,020.93. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Benjamin J. Hindson sold 2,613 shares of the stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total transaction of $121,086.42. Following the completion of the transaction, the insider now owns 283,059 shares in the company, valued at $13,116,954.06. The disclosure for this sale can be found here. Insiders have sold a total of 16,959 shares of company stock worth $773,766 over the last quarter. Company insiders own 10.65% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of 10x Genomics by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 9,011,332 shares of the company's stock valued at $504,274,000 after purchasing an additional 107,815 shares during the period. Goldman Sachs Group Inc. raised its position in shares of 10x Genomics by 0.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 372,873 shares of the company's stock valued at $20,866,000 after purchasing an additional 1,815 shares during the period. Public Employees Retirement System of Ohio raised its position in shares of 10x Genomics by 2.8% during the 4th quarter. Public Employees Retirement System of Ohio now owns 38,446 shares of the company's stock valued at $2,151,000 after purchasing an additional 1,051 shares during the period. Employees Retirement System of Texas bought a new stake in shares of 10x Genomics during the 4th quarter valued at $463,000. Finally, Legal & General Group Plc raised its position in shares of 10x Genomics by 0.6% during the 4th quarter. Legal & General Group Plc now owns 84,355 shares of the company's stock valued at $4,721,000 after purchasing an additional 501 shares during the period. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.